Humanin: Mechanism, Evidence, and Dosing Protocols

Research disclaimer: Humanin is sold for research purposes only and is not intended for human consumption. The information below is drawn from published scientific literature.

Evidence Tier

Animal studies for intervention data. Human observational evidence — circulating Humanin levels correlate with cardiovascular health, Alzheimer’s risk, and longevity across multiple independent cohorts. No human intervention trials. The observational human data is among the strongest in the mitochondrial peptide field.

Humanin sits in the same evidence category as MOTS-c — compelling observational human data, strong animal intervention results, zero controlled human trials. Of the two mitochondrial peptides, Humanin has more extensive human observational data, particularly for Alzheimer’s disease risk.

What Is Humanin?

Humanin is a 24-amino acid peptide encoded within the 16S ribosomal RNA gene of the mitochondrial genome. It was first identified in 2001 by Nishimoto et al. during a screen for genes that could protect neurons from Alzheimer’s-related cell death caused by amyloid precursor protein (APP) mutations. The name “Humanin” reflects its origin — it was discovered in preserved regions of the human occipital cortex that survived amyloid-induced degeneration.

Like MOTS-c, Humanin is a mitochondria-derived peptide (MDP) — it is produced by the mitochondria themselves, not by nuclear-genome-directed ribosomes. It is secreted into the circulation and acts as a hormone — a mitokine — signalling from mitochondria to distant tissues.

Humanin levels in circulation decline with age and are measurably lower in patients with Alzheimer’s disease, cardiovascular disease, and metabolic dysfunction compared to age-matched healthy controls. Offspring of centenarians have higher circulating Humanin than matched controls — a finding from the USC Longevity Genes Project (David Cohen’s group, the same team working on MOTS-c).

Mechanism of Action

Cytoprotection via Receptor Signalling (Primary)

Humanin binds to two receptor systems:

1. FPRL1 (Formyl Peptide Receptor-Like 1) — a G-protein coupled receptor expressed on neurons, immune cells, and cardiac cells. FPRL1 activation by Humanin inhibits apoptosis (programmed cell death) and reduces inflammatory cytokine production.

2. Tripartite receptor complex — composed of WSX-1, CNTFRα, and gp130. This receptor complex mediates STAT3 activation, driving an anti-apoptotic and pro-survival transcriptional programme in neurons and cardiomyocytes.

Amyloid-β Antagonism

Humanin directly binds amyloid-β (the primary toxic aggregate in Alzheimer’s disease) and prevents its interaction with neurons. In cell culture, Humanin is one of the most potent inhibitors of amyloid-β neurotoxicity identified. This is the mechanism that led to its original discovery and remains one of its most studied properties.

Mitochondrial Membrane Stabilisation

Humanin reduces mitochondrial membrane permeability transition — the event that triggers cytochrome c release and apoptosis cascade initiation. This is relevant to ischaemic injury (heart attack, stroke) where mitochondrial membrane disruption causes massive cell death beyond the initially affected zone.

IGF-1 Pathway Modulation

Humanin interacts with components of the IGF-1 signalling pathway — specifically, it binds to IGF-BP3 (IGF binding protein 3) and modulates IGF-1 bioavailability. This connection to the growth hormone/IGF-1 axis links Humanin to one of the most central longevity regulatory pathways.

Insulin Sensitisation

In rodent models of diabetes and metabolic syndrome, Humanin improves insulin sensitivity and reduces fasting glucose. The mechanism involves improved mitochondrial function in peripheral tissues and reduced inflammatory signalling in adipose tissue and liver.

What the Evidence Actually Shows

Alzheimer’s Disease Correlation

Multiple independent studies confirm: Humanin levels in cerebrospinal fluid and blood are significantly lower in Alzheimer’s patients compared to controls, and lower in mild cognitive impairment patients than in cognitively intact elderly. The difference appears early in the disease course. A causal direction has not been established — does Alzheimer’s pathology reduce Humanin, or does low Humanin predispose to Alzheimer’s? Animal data suggests the latter may play a role.

Cardiovascular Risk Correlation

Lower circulating Humanin correlates with higher cardiovascular risk markers — carotid intima-media thickness, coronary artery calcification, and clinical cardiovascular events in prospective cohort data. The correlation persists after adjusting for conventional cardiovascular risk factors.

Centenarian Studies

Offspring of centenarians (long-lived families) have measurably higher Humanin levels than age-matched controls from non-longevity families. This is independent of other metabolic markers and survives multivariable adjustment. It positions Humanin as a potential longevity biomarker — a signal of the biological substrate of exceptional ageing.

Neuroprotection in Animal Models

In rodent models of Alzheimer’s disease, stroke, and traumatic brain injury:

• Humanin reduces amyloid-β-induced cognitive deficits
• Reduces infarct volume after induced stroke
• Protects retinal neurons from degeneration
• Improves cognitive performance in aged mice

These effects are consistent and replicated across multiple labs — unusual in the animal longevity literature where single-group findings are common.

Cardioprotection in Animal Models

Humanin reduces infarct size after myocardial ischaemia-reperfusion injury in rodents. The mechanism involves mitochondrial membrane stabilisation and anti-apoptotic signalling in cardiomyocytes. Dose-dependent effects have been documented.

What Is Not Established

• Any human intervention data — zero controlled trials
• Effective dose in humans for any indication
• Bioavailability and stability of exogenous Humanin after subcutaneous injection in humans
• Whether restoring Humanin levels in low-Humanin elderly reverses any measurable pathology
• Long-term safety profile
• Whether the specific form (Humanin-G, an analog with increased potency, vs native Humanin) is superior for research use

Humanin vs Humanin-G (HNG)

A Gly14-substituted analog of Humanin (Humanin-G or HNG) has been developed and shows approximately 1,000-fold greater potency in cell culture assays. Most recent animal research uses HNG rather than native Humanin. Research suppliers may offer either form — confirm which form is being supplied and adjust dosing expectations accordingly.

Dosing Protocols (Research Context)

No established human dose. All dosing is animal-extrapolated.

Reconstitution: For a 5 mg vial + 2 mL bacteriostatic water → 2,500 µg/mL. A 2 mg dose = 0.8 mL = 80 units on U-100 syringe.

Storage: Lyophilised: −20°C, stable 24+ months. Reconstituted: refrigerate 2–8°C, use within 30 days. Humanin is relatively stable under proper storage conditions.

Summary

Humanin is the best-evidenced mitochondrial peptide for neuroprotection and cardiovascular protection in terms of human observational data. The correlation with Alzheimer’s risk, cardiovascular events, and exceptional longevity across multiple independent cohorts is a remarkable epidemiological signal. The intervention evidence — animal only — is consistent with this observational story. The complete absence of human intervention trials is the hard limit. For researchers working at the frontier of mitochondrial longevity biology, Humanin deserves the same attention as MOTS-c, with the added weight of stronger human observational evidence.

See also: Humanin data page · MOTS-c research review · Mitochondrial Stack: MOTS-c + SS-31